Trial reportJournal of general internal medicine1996
Physician extenders for cost-effective management of hypercholesterolemia.
Trial report in Journal of general internal medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 10 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis.Implementation science : IS · 2021Pooled it
- Reduction in saturated fat intake for cardiovascular disease.The Cochrane database of systematic reviews · 2020Pooled it
- Effects of total fat intake on body fatness in adults.The Cochrane database of systematic reviews · 2020Pooled it
- Reduction in saturated fat intake for cardiovascular disease.The Cochrane database of systematic reviews · 2020Pooled it
- Interventions to improve adherence to lipid-lowering medication.The Cochrane database of systematic reviews · 2016Pooled it
- Effects of total fat intake on body weight.The Cochrane database of systematic reviews · 2015Pooled it
- Reduced or modified dietary fat for preventing cardiovascular disease.The Cochrane database of systematic reviews · 2012Pooled it
- Reduced or modified dietary fat for preventing cardiovascular disease.The Cochrane database of systematic reviews · 2011Pooled it
- Interventions to improve adherence to lipid lowering medication.The Cochrane database of systematic reviews · 2004Pooled it
- Dietary advice given by a dietitian versus other health professional or self-help resources to reduce blood cholesterol.The Cochrane database of systematic reviews · 2001Pooled it
- Expansion and Evaluation of Pharmacist Services in Primary Care.Pharmacy (Basel, Switzerland) · 2020Article
- New Canadian hypertension recommendations. So what?Canadian family physician Medecin de famille canadien · 2000Article
- Cost effectiveness of coronary heart disease prevention strategies in adults.PharmacoEconomics · 1998Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTreatment of elevated cholesterol levels reduces morbidity and mortality from coronary heart disease in high-risk patients, but can be costly. The purpose of this study was to determine whether physician extenders emphasizing diet modification and, when necessary, effective and inexpensive drug algorithms can provide more cost-effective therapy than conventional care.
designRandomized controlled trial.
settingA Department of Veterans Affairs Medical Center. PATIENTS: Two hundred forty-seven veterans with type IIa hypercholesterolemia.
interventionsPatients assigned to either a cholesterol treatment program (CTP) or usual health care provided by general internists (UHC). CTP included intensive dietary therapy administered by a registered dietitian utilizing individual and group counseling and drug therapy initiated by physician extenders for those failing to achieve goal low-density lipoprotein (LDL) levels with diet alone. A drug selection algorithm for CTP subjects utilized niacin as initial therapy followed by bile acid sequestrants and lovastatin. Subjects were followed prospectively for 2 years. MEASUREMENTS: Primary outcome measurements were effectiveness of therapy defined as reductions in LDL cholesterol (LDL-C), and whether goal LDL-C levels were achieved; costs of therapy; and cost-effectiveness defined as the cost per unit reduction in the LDL-C. MAIN
resultsTotal program costs were higher for CTP patients than for UHC patients ($659 +/- $43 vs $477 +/- $42 per patient, p < .001). However, at 24 months the patients in CTP were more likely to achieve LDL goal levels (65% vs 44%, p < .005), and also achieved greater reductions in LDL-C 27% +/- 2% vs 14% +/- 2% at 24 months, p < .001). Program costs per unit (mmol/L) reduction in the LDL-C, a measure of cost-effectiveness, was significantly lower for CTP ($758 +/- $58 vs $1,058 +/- $70, p = .002).
conclusionsAlthough more expensive than usual care, the greater effectiveness of physician extenders implementing cholesterol treatment algorithms resulted in more cost-effective therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.